ClinicalTrials.gg
CompletedNCT05526248ARAMONUpdated Mar 11, 2026Results posted

A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide

A Phase 2 interventional study of Darolutamide(BAY1841788, Nubeqa) and Enzalutamide in Biochemically Recurrent Prostate Cancer, sponsored by Bayer. Completed at 5 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing darolutamide in Prostatic Neoplasms — 29 open to participants now, 40 under way, 10 of them phase 3. darolutamide · Prostatic Neoplasms.

Enrollment
49th of 59
28 · median 80
Started
2022
with 4 others
Phase 2
29 of 59
16 open now
Registered
30th of 59
by date
Lead sponsor
10 of 59
Bayer

Among the 59 studies testing darolutamide in Prostatic Neoplasms, this one is the 49th largest by enrollment, is one of 5 that started in 2022, is one of 29 in phase 2, and was the 30th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

29 of the 59 studies testing darolutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About darolutamide

darolutamide: first FDA approval 2019 (NUBEQA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing darolutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Researchers are looking for a better way to treat men who have biochemically recurrent hormone-naïve prostate cancer.

Hormone-naïve prostate cancer is a prostate cancer that has not yet been treated with hormonal therapy including androgen deprivation therapy (ADT). Biochemically recurrence (BCR) means that patients who received local treatment (surgery or radiation therapy) for prostate cancer now present with a rise in the blood level of a specific protein called PSA (prostate-specific antigen) but no detectable cancer or cancer spreading after a treatment that aimed to cure their prostate cancer (e.g. surgery and radiation). This may mean that the cancer has come back as the PSA level can be taken as a marker for prostate cancer development. Although men with BCR may not have symptoms for many years, proper treatment for BCR is important as the cancer may spread to other parts of the body in 7-8 years.

In prostate cancer patients, male sex hormones like testosterone (also called androgens) can sometimes help the cancer spread and grow. To reduce androgen levels in these patients, androgen deprivation therapy (ADT) is often used.

Second generation androgen receptor inhibitors including Darolutamide and Enzalutamide are available for the treatment of prostate cancer in addition to ADT. These inhibitors work by blocking androgen receptors and preventing it from attaching to proteins in cancer cells in the prostate. It is already known that men with prostate cancer benefit from these treatments. But besides benefits, Darolutamide and Enzalutamide are not without side effects.

Clinical studies have shown that treatment with Enzalutamide increase testosterone level in serum, probably because it can pass blood brain barrier and goes into the central nervous system (CNS). The increased testosterone levels are thought to cause some specific side effects including so called feminizing side effects like overdevelopment of the breast tissue in men, and breast tenderness. Darolutamide has a distinct chemical structure and reduced ability to enter the CNS compared with Enzalutamide. That means that Darolutamide potentially leads to fewer and less severe side effects than Enzalutamide.

In this study researchers will collect more data to learn to what extent Darolutamide affects serum testosterone levels in men with BCR in hormone-naïve prostate cancer. This study will consist of 2 stages. In stage 1 (also called lead-in phase) all participants will take Darolutamide by mouth twice a day. The study team will monitor and measure testosterone levels in the blood after:

  • 12 weeks
  • 24 weeks and
  • 52 weeks of treatment.

The second stage (also called randomized phase) is conditional and depends on the results from the stage 1. It will be conducted if after 24 weeks of treatment with Darolutamide in stage 1:

  • a mean change in blood testosterone levels is below 45% and
  • if the feminizing side effects (including overdevelopment of the breast tissue in men, and breast tenderness) will occur less frequently than previously reported.

In the second stage of this study all participants will be randomly (by chance) assigned into two treatment groups, taking either Darolutamide twice daily or Enzalutamide once daily by mouth for a minimum of 12 and a maximum of 52 weeks.

During both stages of this study the study team will:

  • do physical examinations
  • take blood and urine samples
  • examine heart health using ECG
  • examine heart and lung health using CPET
  • check bone density using x-ray scan (DEXA)
  • check vital signs
  • check if the participants' cancer has grown and/or spread using CT (computed tomography) or MRI (magnetic resonance imaging) and, if needed, bone scan
  • ask the participants questions about how they are feeling and what adverse events they are having.

An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.

The study participants who receive Darolutamide in stage 2 can continue to receive their treatments as long as they benefit from the treatment. The participants from the Enzalutamide group can also switch to treatment with Darolutamide after finishing stage 2. The study team will continue to check the participants' health and collect information about medical problems that might be related to Darolutamide until up to 30 days of last dose for those participants who continue on treatment with Darolutamide.

03

Conditions studied

  • Biochemically Recurrent Prostate Cancer

Browse trials for

Keywords

  • Hormone-naive prostate cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male of ≥ 18 years of age.
  • Patients must have or cytologically confirmed adenocarcinoma of the prostate.
  • Prior treatment with primary radical prostatectomy or definitive RT for localized prostate cancer
  • Patients must have PSA ≥0.2 ng/mL after ART or SRT post-RP or after RP in participants who are unfit for ART or SRT, OR PSA ≥2 ng/mL above the nadir after primary RT only. (RP, radical prostatectomy; ART, radiotherapy; SRT, salvage radiotherapy; RT primary radiotherapy)
  • The presence of \< 5 asymptomatic lesions on conventional or PSMA-PET based imaging methods permitted. Lesions that need treatment with any opioid based analgetic are considered symptomatic
  • PSADT ≤ 20 months calculated per PCWG3 + 1.1 per Scher et al. (Scher et al. 2016) and MSKCC nomogram.
  • ECOG (PS) of 0 - 1.
  • Serum testosterone >150 ng/dl.
  • Patients must have adequate organ function within 4 weeks before the first dose of study intervention.
  • More than 30 days (or 5 half-lives) (whichever is longer) since prior participation in another clinical trial with an medicinal product.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with ADT of up to 6 months for localized disease is permitted but not if during the prior 6 months before first dose of study intervention. Plan to initiate ADT during the trial period is not allowed.
  • Radiation therapy or major surgery within 4 weeks of screening.
  • Systemic within 3 months prior to the first dose or study intervention was expected to require systemic glucocorticoids during the study period
  • Had any of the following within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, congestive heart failure ( Class III or IV)
  • Uncontrolled hypertension
  • A gastrointestinal disorder or procedure which is expected to interfere significantly with absorption of study intervention.
  • Prior history of a with the exception of basal cell, squamous cell carcinoma of the skin, and superficial bladder cancer.
  • Prior treatment with:

    • Second-generation androgen receptor (AR) inhibitors such as enzalutamide, apalutamide, darolutamide other AR inhibitors
    • or Cytochrome P17 enzyme inhibitor such as abiraterone acetate as antineoplastic treatment for prostate cancer
  • Prior history of gynecomastia
  • Use of herbal products that may have had hormonal anti-prostate cancer activity or were known to decrease PSA levels (e.g., saw palmetto) within 4 weeks before the first dose of study intervention
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Lead-in phase: Darolutamide treatment

    Darolutamide treatment arm is single cohort in lead-in phase.

    Drug: Darolutamide(BAY1841788, Nubeqa)

  • Experimental
    Randomized phase: Darolutamide treatment

    The conduct of the randomized phase is dependent on the results of the lead-in phase.

    Drug: Darolutamide(BAY1841788, Nubeqa)

  • Active comparator
    Randomized phase: Enzalutamide treatment

    The conduct of the randomized phase is dependent on the results of the lead-in phase.

    Drug: Enzalutamide

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change in Serum Testosterone

    Time frame: From baseline to week 12

Secondary outcomes

  1. Percent Change in Serum Testosterone

    Time frame: From baseline to week 24 and 52

  2. Number of Participants With Different Serum Prostate-specific Antigen (PSA) Response

    PSA50 is defined as a ≥50% reduction of the PSA level compared to the baseline value, confirmed by a second subsequent PSA value with a ≥50% reduction from baseline 3 or more weeks later.

    Time frame: At week 4.12.24.36.52

07

Results

Posted Oct 15, 2025

Participant flow

A total of 28 participants were screened and signed the informed consent form for the study. Three participants were screen failures and did not complete screening. The study was conducted at five centers in the United States from 19 Dec 2022 (First Patient First Visit) to 4 Dec 2024 (Last Patient Last Visit). The randomized phase was never started based on the results of the lead-in phase.

Participant flow — Overall Study
MilestoneLead-in Phase: Darolutamide Treatment
Started24
All participants in the lead-in phase had been on treatment for 12 weeks24
Completed20
Not completed4
Withdrew: Lost to follow-up1
Withdrew: Adverse event2
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPercent Change in Serum Testosterone
Time frame:
From baseline to week 12
Reported as:
Mean · percentage (%)
Percent Change in Serum Testosterone
percentage (%)Lead-in Phase: Darolutamide Treatment
Percent Change in Serum Testosterone53.46 (33.44 to 76.48)
SecondaryPercent Change in Serum Testosterone
Time frame:
From baseline to week 24 and 52
Reported as:
Mean · Percentage (%)
Percent Change in Serum Testosterone
Percentage (%)Lead-in Phase: Darolutamide Treatment
Mean percent change from baseline at Week 2456.25 (39.87 to 74.55)
Mean percent change from baseline at Week 5248.49 (32.76 to 66.08)
SecondaryNumber of Participants With Different Serum Prostate-specific Antigen (PSA) Response

PSA50 is defined as a ≥50% reduction of the PSA level compared to the baseline value, confirmed by a second subsequent PSA value with a ≥50% reduction from baseline 3 or more weeks later.

Time frame:
At week 4.12.24.36.52
Reported as:
Count of participants · Participants
Number of Participants With Different Serum Prostate-specific Antigen (PSA) Response
ParticipantsLead-in Phase: Darolutamide Treatment
Number of participants with confirmed PSA50 response at Week 423
Number of participants with confirmed PSA50 response at Week 1223
Number of participants with confirmed PSA50 response at Week 2423
Number of participants with confirmed PSA50 response at Week 3623
Number of participants with confirmed PSA50 response at Week 5223
Number of participants with confirmed PSA50 response any time23

Adverse events

Collected over Treatment-emergent AE (TEAE) was defined as any event arising or worsening after the first dose of study drug until 30 days after the last dose of study drug, up to 13 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Darolutamide 600 mg BID0/24 (0%)3/24 (12.5%)24/24 (100%)
Most frequent serious events
Most frequent serious events
EventDarolutamide 600 mg BID
Retinal detachmentEye disorders1/24
Rectal haemorrhageGastrointestinal disorders1/24
PyrexiaGeneral disorders1/24
PneumoniaInfections and infestations1/24
CoughRespiratory, thoracic and mediastinal disorders1/24
DyspnoeaRespiratory, thoracic and mediastinal disorders1/24
Most frequent other events
Showing 10 of 75
Most frequent other events
EventDarolutamide 600 mg BID
GynaecomastiaReproductive system and breast disorders19/24
FatigueGeneral disorders7/24
DiarrhoeaGastrointestinal disorders4/24
Decreased appetiteMetabolism and nutrition disorders4/24
DizzinessNervous system disorders4/24
Breast painReproductive system and breast disorders4/24
HypertensionVascular disorders4/24
ConstipationGastrointestinal disorders3/24
ArthralgiaMusculoskeletal and connective tissue disorders3/24
Muscular weaknessMusculoskeletal and connective tissue disorders3/24

Baseline characteristics

The evaluable set was defined as all enrolled participants having testosterone data at baseline and week 12. Enrolled participants include those who signed informed consent and met all inclusion and none of the exclusion criteria.

Age, Continuous
Age, Continuous(Years)Lead-in Phase: Darolutamide Treatment
Mean72.1 ± 7.5
Sex: Female, Male
Sex: Female, Male(Participants)Lead-in Phase: Darolutamide Treatment
Female0
Male23
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lead-in Phase: Darolutamide Treatment
Hispanic or Latino3
Not Hispanic or Latino19
Unknown or Not Reported1
Number of participants with different baseline value of ECOG Performance Status
Number of participants with different baseline value of ECOG Performance Status(Participants)Lead-in Phase: Darolutamide Treatment
021
12
Number of participants with different Gleason score of prostate cancer at initial diagnosis
Number of participants with different Gleason score of prostate cancer at initial diagnosis(Participants)Lead-in Phase: Darolutamide Treatment
≤ 66
= 714
≥ 82
Unknown1
Number of participants with Bone lesions at baseline
Number of participants with Bone lesions at baseline(Participants)Lead-in Phase: Darolutamide Treatment
No18
Yes5
Number of bone lesions at baseline
Number of bone lesions at baseline(Participants)Lead-in Phase: Darolutamide Treatment
13
42
Number of participants with different renal impairment
Number of participants with different renal impairment(Participants)Lead-in Phase: Darolutamide Treatment
Normal: eGFR ≥ 90 mL/min6
Mild impairment: 60 ≤ eGFR < 90 mL/min13
Moderate impairment: 30 ≤ eGFR < 60 mL/min4
08

Study locations

5 sites
  • Unio Specialty Care - Urology - Sherman Oaks
    Sherman Oaks, California 91411, United States
  • Mass General Cancer Center
    Boston, Massachusetts 02114-2696, United States
  • Beth Israel Deaconess Medical Center - Oncology
    Boston, Massachusetts 02215, United States
  • Memorial Sloan Kettering Cancer Center New York - Main Campus
    New York, New York 10065, United States
  • Central Ohio Urology Group - Gahanna
    Gahanna, Ohio 43230, United States
09

References and documents

Publications

  • Laccetti AL, Smith MR, Scher HI, Nowfar S, Einstein D, Martin B, Adorjan P, Dissanayake M, Verholen F, Gao X. ARAMON, a phase 2 open-label trial of darolutamide monotherapy in patients with biochemical recurrence or oligometastatic castration-sensitive prostate cancer after radical prostatectomy or primary radiotherapy. Eur Urol Focus. 2026 Feb 26:S2405-4569(26)00034-9. doi: 10.1016/j.euf.2026.02.005. Online ahead of print. PubMed 41760423 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Aug 2024, 20 months.

Results were first posted in Oct 2025, 1 year 1 month after primary completion.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 20 months is below that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2022
First posted
Sep 2, 2022
StartActual
Dec 19, 2022
Primary completionActual
Aug 20, 2024
CompletionActual
Dec 4, 2024
Results first posted
Oct 15, 2025
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05526248
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 2, 2022
Start date
Dec 19, 2022
Primary completion
Aug 20, 2024
Completion
Dec 4, 2024
Results posted
Oct 15, 2025
Last update
Mar 11, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Darolutamide

Start the discussion